TY  - GEN
AU  - Chastre, Jean
AU  - François, Bruno
AU  - Bourgeois, Marc
AU  - Komnos, Apostolos
AU  - Ferrer, Ricard
AU  - Rahav, Galia
AU  - De Schryver, Nicolas
AU  - Lepape, Alain
AU  - Koksal, Iftihar
AU  - Luyt, Charles-Edouard
AU  - Sánchez-García, Miguel
AU  - Torres, Antoni
AU  - Eggimann, Philippe
AU  - Koulenti, Despoina
AU  - Holland, Thomas L
AU  - Ali, Omar
AU  - Shoemaker, Kathryn
AU  - Ren, Pin
AU  - Sauser, Julien
AU  - Ruzin, Alexey
AU  - Tabor, David E
AU  - Akhgar, Ahmad
AU  - Wu, Yuling
AU  - Jiang, Yu
AU  - DiGiandomenico, Antonio
AU  - Colbert, Susan
AU  - Vandamme, Drieke
AU  - Coenjaerts, Frank
AU  - Malhotra-Kumar, Surbhi
AU  - Timbermont, Leen
AU  - Oliver, Antonio
AU  - Barraud, Olivier
AU  - Bellamy, Terramika
AU  - Bonten, Marc
AU  - Goossens, Herman
AU  - Reisner, Colin
AU  - Esser, Mark
AU  - Jafri, Hasan S
PY  - 2022
DO  - 10.1186/s13054-022-04204-9
UR  - https://hdl.handle.net/20.500.12105/23515
AB  - Background: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia...
LA  - eng
KW  - Pneumonia, Ventilator-Associated
KW  - Intensive Care Units
KW  - Antibodies, Monoclonal
KW  - Animals
KW  - Treatment Outcome
KW  - Humans
KW  - Respiration, Artificial
KW  - Adolescent
KW  - Pseudomonas aeruginosa
KW  - Double-Blind Method
KW  - Pseudomonas Infections
TI  - Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
TY  - research article
ER  -